QLGN
Qualigen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About QLGN
Qualigen Therapeutics, Inc.
A biotech company that develops new therapeutic products for cancer and infectious diseases
5857 Owens Avenue, Suite 300, Carlsbad, California 92008
--
Qualigen Therapeutics, Inc., incorporated on March 29, 2004, is a Nevada limited liability company named Ritter Natural Sciences, LLC, which was converted to a Delaware corporation on September 16, 2008. The company is an early stage clinical treatment company focused on developing treatments for adult and pediatric cancers. Their business now includes an early clinical stage treatment program (QN-302) and a preclinical treatment program (Pan-RAS).
Company Financials
EPS
QLGN has released its 2023 Q3 earnings. EPS was reported at -0.64, versus the expected -0.92, beating expectations. The chart below visualizes how QLGN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
